![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Santarus Ulcerative Colitis Drug to Hit Shelves in March
Santarus Ulcerative Colitis Drug to Hit Shelves in March
January 23, 2013
The FDA has approved Santarus’ daily extended-release drug Uceris to induce remission of mild to moderate active ulcerative colitis, a form of inflammatory bowel disease. The company plans to launch the drug in March and expects peak annual sales of up to $300 million. Santarus also announced plans to increase its number of sales representatives by 50 percent to 235.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
21Oct